vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Snail, Inc. (SNAL). Click either name above to swap in a different company.
Snail, Inc. is the larger business by last-quarter revenue ($25.1M vs $15.0M, roughly 1.7× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -3.4%, a 5.2% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -4.2%). Over the past eight quarters, Snail, Inc.'s revenue compounded faster (33.4% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Suzhou Snail Digital Technology Co., Ltd., doing business as Snail, is a Chinese video game company and a Virtual Network Operator headquartered in Suzhou, China, which has branches Snail Games and Snail Mobile. Its division, Snail USA, markets Snail Games products in North America, South America, & Europe. Snail Games products include massively multiplayer online (MMOs), real-time strategy (RTS), and casual games. Its global registered user base has reached over 70 million accounts. The U.S....
CSBR vs SNAL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $25.1M |
| Net Profit | $268.0K | $-862.2K |
| Gross Margin | 51.7% | 38.3% |
| Operating Margin | 1.2% | -6.0% |
| Net Margin | 1.8% | -3.4% |
| Revenue YoY | 11.5% | -4.2% |
| Net Profit YoY | -63.2% | -177.0% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $25.1M | ||
| Q3 25 | $14.0M | $13.8M | ||
| Q2 25 | $12.4M | $22.2M | ||
| Q1 25 | $17.0M | $20.1M | ||
| Q4 24 | $13.5M | $26.2M | ||
| Q3 24 | $14.1M | $22.5M | ||
| Q2 24 | $14.0M | $21.6M | ||
| Q1 24 | $12.0M | $14.1M |
| Q4 25 | $268.0K | $-862.2K | ||
| Q3 25 | $-436.0K | $-7.9M | ||
| Q2 25 | $-1.8M | $-16.6M | ||
| Q1 25 | $4.5M | $-1.9M | ||
| Q4 24 | $728.0K | $1.1M | ||
| Q3 24 | $1.3M | $235.1K | ||
| Q2 24 | $-109.0K | $2.3M | ||
| Q1 24 | $-2.5M | $-1.8M |
| Q4 25 | 51.7% | 38.3% | ||
| Q3 25 | 42.9% | 0.1% | ||
| Q2 25 | 41.1% | 31.3% | ||
| Q1 25 | 61.2% | 29.1% | ||
| Q4 24 | 44.9% | 43.3% | ||
| Q3 24 | 49.7% | 38.6% | ||
| Q2 24 | 48.2% | 37.5% | ||
| Q1 24 | 34.7% | 14.7% |
| Q4 25 | 1.2% | -6.0% | ||
| Q3 25 | -3.8% | -71.3% | ||
| Q2 25 | -16.2% | -8.2% | ||
| Q1 25 | 26.4% | -20.4% | ||
| Q4 24 | 5.4% | 11.5% | ||
| Q3 24 | 9.5% | 1.8% | ||
| Q2 24 | -1.9% | 12.4% | ||
| Q1 24 | -21.4% | -15.6% |
| Q4 25 | 1.8% | -3.4% | ||
| Q3 25 | -3.1% | -56.9% | ||
| Q2 25 | -14.9% | -74.7% | ||
| Q1 25 | 26.4% | -9.7% | ||
| Q4 24 | 5.4% | 4.3% | ||
| Q3 24 | 9.3% | 1.0% | ||
| Q2 24 | -0.8% | 10.4% | ||
| Q1 24 | -21.1% | -12.6% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.12 | $-0.44 | ||
| Q1 25 | $0.31 | $-0.06 | ||
| Q4 24 | $0.05 | $0.03 | ||
| Q3 24 | $0.09 | $0.01 | ||
| Q2 24 | $-0.01 | $0.06 | ||
| Q1 24 | $-0.19 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $8.6M |
| Total DebtLower is stronger | — | $14.6M |
| Stockholders' EquityBook value | $4.2M | $-16.4M |
| Total Assets | $30.2M | $59.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $8.6M | ||
| Q3 25 | $10.3M | $12.3M | ||
| Q2 25 | $9.8M | $7.9M | ||
| Q1 25 | $3.2M | $9.4M | ||
| Q4 24 | $2.8M | $7.3M | ||
| Q3 24 | $2.9M | $10.6M | ||
| Q2 24 | $2.6M | $15.5M | ||
| Q1 24 | $4.5M | $16.1M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $10.5M | ||
| Q2 25 | — | $11.8M | ||
| Q1 25 | — | $9.0M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $5.8M | ||
| Q1 24 | — | $6.5M |
| Q4 25 | $4.2M | $-16.4M | ||
| Q3 25 | $3.5M | $-15.6M | ||
| Q2 25 | $3.8M | $-8.0M | ||
| Q1 25 | $5.5M | $9.1M | ||
| Q4 24 | $681.0K | $9.7M | ||
| Q3 24 | $-332.0K | $8.2M | ||
| Q2 24 | $-1.9M | $7.9M | ||
| Q1 24 | $-2.1M | $5.6M |
| Q4 25 | $30.2M | $59.3M | ||
| Q3 25 | $30.5M | $51.1M | ||
| Q2 25 | $32.3M | $58.0M | ||
| Q1 25 | $30.6M | $64.5M | ||
| Q4 24 | $25.2M | $62.2M | ||
| Q3 24 | $24.9M | $66.8M | ||
| Q2 24 | $26.1M | $75.4M | ||
| Q1 24 | $26.8M | $78.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.99× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.73× | ||
| Q1 24 | — | 1.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-5.3M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-5.3M | ||
| Q3 25 | $600.0K | $6.6M | ||
| Q2 25 | $6.9M | $-3.2M | ||
| Q1 25 | $490.0K | $764.5K | ||
| Q4 24 | $-283.0K | $-3.6M | ||
| Q3 24 | $311.0K | $-5.0M | ||
| Q2 24 | $-1.8M | $206.6K | ||
| Q1 24 | $-919.0K | $6.8M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | -3.21× | ||
| Q3 24 | 0.24× | -21.05× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
SNAL
| Pc | $14.7M | 59% |
| Platform Three | $5.2M | 21% |
| Platform Two | $3.3M | 13% |
| Sales Channel Directly To Consumer Mobile Sale | $1.6M | 6% |
